



JAAD Game Changers*:
Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center

*A game changer is a short narrative stating how an article that originally appeared in *JAAD* changed the game of dermatology. **NOTE:** The Game Changer author is not the original author of the article. Please see the reference section for the original author information.

Wendi Wohltmann, MD
San Antonio, Texas

Capsule Summary

- Sweet syndrome may be classic, malignancy associated, or drug induced.
- Leukopenia, anemia, thrombocytopenia, absence of arthralgia, and histiocytoid or subcutaneous histopathology were associated with malignancy in our cohort.
- When caring for patients with Sweet syndrome, dermatologists should be aware of the potential association of certain clinicopathologic features with malignancy.

How did this article change the practice of dermatology?

This large retrospective analysis highlights clinicopathologic clues (leukopenia, anemia, thrombocytopenia, absence of arthralgia, and histiocytoid or subcutaneous histopathology) potentially associated with malignancy in Sweet syndrome patients. This work can help clinicians determine which patients should undergo a malignancy work-up.¹

San Antonio Uniformed Services Health Education Consortium.

Funding sources: None.

Conflicts of interest: None disclosed.

Correspondence to: Wendi Wohltmann, MD, Department of Dermatology, San Antonio Uniformed Services Health Education Consortium, 1100 Wilford Hall Loop, Bldg 4554, 59 MDSP/Dermatology, JBSA Lackland, TX 78236. E-mail: wwohltmann@hotmail.com.

Published by Elsevier on behalf of the American Academy of Dermatology, Inc.

<https://doi.org/10.1016/j.jaad.2019.06.1294>

REFERENCE

1. Nelson CA, Noe MH, McMahon CM, et al. Sweet syndrome in patients with and without malignancy: a retrospective analysis of 83 patients from a tertiary academic referral center. *J Am Acad Dermatol*. 2018;78(2):303-309.